{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:41:40Z","timestamp":1790106100675,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T00:00:00Z","timestamp":1441324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1208\/s12248-015-9821-x","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T14:39:56Z","timestamp":1441377596000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Evaluation of IgE Antibodies to Omalizumab (Xolair\u00ae) and Their Potential Correlation to Anaphylaxis"],"prefix":"10.1208","volume":"18","author":[{"given":"Dana L.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald R.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry B.","family":"Lowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloumeh Kadkhodayan","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,4]]},"reference":[{"key":"9821_CR1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","volume":"120","author":"S Limb","year":"2007","unstructured":"Limb S, Starke P, Lee C, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120:1378\u201381.","journal-title":"J Allergy Clin Immunol"},{"key":"9821_CR2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jaci.2005.01.009","volume":"115","author":"H Sampson","year":"2005","unstructured":"Sampson H, Munoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005;115:584\u201391.","journal-title":"J Allergy Clin Immunol"},{"key":"9821_CR3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","volume":"117","author":"H Sampson","year":"2006","unstructured":"Sampson H, Munoz-Furlong A, Campbell RL, Adkinson Jr NF, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report\u2014Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"9821_CR4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-61779-931-0_18","volume-title":"Methods in molecular biology: antibody methods and protocols","author":"RF Kelley","year":"2012","unstructured":"Kelley RF, Meng YG. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function G. In: Proetzel H, Ebersbach H, editors. Methods in molecular biology: antibody methods and protocols. New York, NY: 901 Humana Press; 2012. p. 277\u201393."},{"key":"9821_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","volume":"68","author":"PJ Lowe","year":"2009","unstructured":"Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68:61\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"9821_CR6","doi-asserted-by":"crossref","unstructured":"Phil Leiberman. Definition and criteria for the diagnoses of anaphylaxis. Mariana C. Castells, editor. Anaphylaxis and hypersensitivity reactions. Humana Press, Springer New York; 2010. P. 1\u201313.","DOI":"10.1007\/978-1-60327-951-2_1"},{"key":"9821_CR7","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowka A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572\u201381.","journal-title":"N Engl J Med"},{"key":"9821_CR8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567\u201378.","journal-title":"N Engl J Med"},{"key":"9821_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","volume":"115","author":"S Holgate","year":"2005","unstructured":"Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role in IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"9821_CR10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","volume":"98","author":"A Cheifetz","year":"2003","unstructured":"Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315\u201324.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"9821_CR11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000055403","volume":"61","author":"N Cook-Bruns","year":"2001","unstructured":"Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001;61 Suppl 2:58\u201366.","journal-title":"Oncology"},{"key":"9821_CR12","unstructured":"Omalizumab (marketed as Xolair\u00ae) Information. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research, 2007. (Accessed February 19, 2008, at http:\/\/www.fda.gov\/cder\/drug\/infopage\/omalizumab\/default.htm .)"},{"key":"9821_CR13","unstructured":"Erbitux (cetuximab). New York: Im-Clone Systems Incorporated and Bristol-Myers Squibb, 2007 (drug product label)."},{"key":"9821_CR14","first-page":"250","volume":"72","author":"A Cheifetz","year":"2005","unstructured":"Cheifetz A, Mayer L. Monoclonal anti-bodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250\u20136.","journal-title":"Mt Sinai J Med"},{"key":"9821_CR15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose. N Engl J Med. 2008;358:1109\u201317.","journal-title":"N Engl J Med"},{"issue":"1","key":"9821_CR16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cam4.333","volume":"4","author":"S Maier","year":"2015","unstructured":"Maier S, Chung CH, Morse M, Platts-Mills T, Townes L, Mukhopadhyay P, et al. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med. 2015;4(1):36\u201342.","journal-title":"Cancer Med"},{"key":"9821_CR17","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2007.11.7812","volume":"25","author":"BH O'Neil","year":"2007","unstructured":"O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007;25:3644\u20138.","journal-title":"J Clin Oncol"},{"key":"9821_CR18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2500\/aap.2007.28.2951","volume":"28","author":"BI Oyefara","year":"2007","unstructured":"Oyefara BI, Bahna SL. Delayed food-dependent, exercise-induced anaphylaxis. Allergy Asthma Proc. 2007;28:64\u20136.","journal-title":"Allergy Asthma Proc"},{"key":"9821_CR19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.anai.2010.03.004","volume":"104","author":"C Iribarren","year":"2010","unstructured":"Iribarren C, Tolstykh IV, Miller MK, Eisner MD. Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system. Ann Allergy Asthma Immunol. 2010;104:371\u20137.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-015-9821-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-015-9821-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-015-9821-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T01:59:47Z","timestamp":1567130387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-015-9821-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["9821"],"URL":"https:\/\/doi.org\/10.1208\/s12248-015-9821-x","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,4]]}}}